WeTrials
Active, not recruiting

A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis

What is this study?

This study is testing an experimental medication called fenebrutinib to see how well it works and if it is safe for adults with relapsing multiple sclerosis. Researchers want to compare it against a standard treatment, teriflunomide, to help reduce relapses and slow down disability progression.

Who can participate?

Adults with a confirmed diagnosis of relapsing multiple sclerosis who meet specific physical mobility and dexterity requirements may be able to join. However, people with certain types of progressive multiple sclerosis, active infections, or those who are pregnant or nursing cannot participate.

What will happen?

Participants will be randomly assigned to receive either the experimental drug fenebrutinib or the standard medication teriflunomide. You will be monitored closely by the study team for safety and to see how your condition responds to the treatment over time.

Where and when?

This study is taking place at multiple locations, including sites in Alabama and Arizona in the United States. The study is currently active, though it is not actively looking for new participants right now.

Key Points
  • 1Testing fenebrutinib against an existing MS treatment called teriflunomide
  • 2Focuses on adults with relapsing forms of multiple sclerosis
  • 3Participants receive careful medical monitoring and support throughout the trial

Related video

ECTRIMS podcast: investigators explain the FENhance 1 and 2 results (April 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Relapsing Multiple Sclerosis

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.